8-K Announcements
6Material company update
May 15, 2026·SEC
Material company update
Mar 31, 2026·SEC
Material company update
Mar 27, 2026·SEC
MiNK Therapeutics, Inc.(INKT)Earnings, Financials & Key Ratios
INKT•NASDAQ
$11.21
Price updated Jun 27, 2026
AboutMiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.Show more
- Revenue$0
- EBITDA-$12M-17.9%
- Net Income-$12M-15.9%
- EPS (Diluted)-2.93-4.6%
INKT Price & Volume
MiNK Therapeutics, Inc. (INKT) stock price & volume — 10-year historical chart
Loading chart...
Clinical Stage Liquidity Risks Obscure Pipeline
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical stage liquidity dependence
"MiNK Therapeutics remains a pre-commercial entity with zero revenue generation, relying entirely on external capital to fund its AGENT-797 development program. The firm's financial profile is heavily distorted by massive stock-based compensation, which reached $2.7 billion in 2025Q4, and significant data anomalies regarding cash reserves. Investors should exercise extreme caution given the persistent erosion of the equity base into a $12.7 million deficit as of 2026Q1."
Verdict Logic
the company's reliance on external capital is underscored by a persistent negative free cash flow and a concerning equity deficit of $12.7 million as of 2026Q1.
INKT Growth Metrics
MiNK Therapeutics, Inc. (INKT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-28.04%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-11.42%
Return on Capital
10 Years-963.33%
5 Years-963.33%
3 Years-1699.76%
Last Year-1034.24%
INKT Recent Earnings
MiNK Therapeutics, Inc. (INKT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$0.57+26.0%
$0.77
Rev
—
—
Q2 2026
Mar 17, 2026Metric
Actual
Est
EPS
$0.52+23.5%
$0.68
Rev
—
—
Q4 2025
Nov 14, 2025Metric
Actual
Est
EPS
$0.65+24.4%
$0.86
Rev
—
—
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$1.06-92.7%
$0.55
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.57vs $0.77+26.0% | — |
| Q2 2026 | Mar 17, 2026 | $0.52vs $0.68+23.5% | — |
| Q4 2025 | Nov 14, 2025 | $0.65vs $0.86+24.4% | — |
| Q3 2025 | Aug 14, 2025 | $1.06vs $0.55-92.7% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for MiNK Therapeutics, Inc. (INKT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $11.21 | $55.82M | -3.82 | — | — | — | — | |
| $2.10 | $244.77M | -1.83 | -51.24% | -2056.79% | -58.89% | — | |
| $99.95 | $4.87B | -26.44 | — | — | -244.61% | — | |
| $0.97 | $125.86M | -0.97 | 266.65% | -1360.61% | -91.94% | — | |
| $38.85 | $7.98B | -14.03 | — | — | -68.16% | — | |
| $4.25 | $1.52B | -3.90 | 60.6% | -123.9% | -50.17% | — |
Compare INKT vs Peers
MiNK Therapeutics, Inc. (INKT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
INKT SEC Filings & Documents
MiNK Therapeutics, Inc. (INKT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when INKT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
INKT Frequently Asked Questions
MiNK Therapeutics, Inc. (INKT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is INKT profitable?
MiNK Therapeutics, Inc. (INKT) reported a net loss of $12.5M for fiscal year 2025.
Dividend & Returns
What is MiNK Therapeutics, Inc.'s free cash flow?
MiNK Therapeutics, Inc. (INKT) had negative free cash flow of $1.74B in fiscal year 2025, likely due to heavy capital investments.